Abstract:Background: Cardiac hypertrophy is an important prepathology of, and will ultimately lead to, heart failure. However, the mechanisms underlying pathological cardiac hypertrophy remain largely unknown. This study aims to elucidate the effects and mechanisms of HINT1 (histidine triad nucleotide-binding protein 1) in cardiac hypertrophy and heart failure. Methods: HINT1 was downregulated in human hypertrophic heart samples compared with nonhypertrophic samples by mass spectrometry analysis. Hint1 knockout mice were challenged with transverse aortic constriction surgery. Cardiac-specific overexpression of HINT1 mice by intravenous injection of adeno-associated virus 9 (AAV9)-encoding Hint1 under the cTnT (cardiac troponin T) promoter were subjected to transverse aortic construction. Unbiased transcriptional analyses were used to identify the downstream targets of HINT1. AAV9 bearing shRNA against Hoxa5 (homeobox A5) was administrated to investigate whether the effects of HINT1 on cardiac hypertrophy were HOXA5-dependent. RNA sequencing analysis was performed to recapitulate possible changes in transcriptome profile.Coimmunoprecipitation assays and cellular fractionation analyses were conducted to examine the mechanism by which HINT1 regulates the expression of HOXA5. Results: The reduction of HINT1 expression was observed in the hearts of hypertrophic patients and pressure overloaded-induced hypertrophic mice, respectively. In Hint1-deficient mice, cardiac hypertrophy deteriorated after transverse aortic construction. Conversely, cardiac-specific overexpression of HINT1 alleviated cardiac hypertrophy and dysfunction. Unbiased profiler polymerase chain reaction array showed HOXA5 is 1 target for HINT1, and the cardioprotective role of HINT1 was abolished by HOXA5 knockdown in vivo. Hoxa5 was identified to affect hypertrophy through the TGF-beta (transforming growth factor beta) signal pathway. Mechanically, HINT1 inhibited PKC beta 1 (protein kinase C beta type 1) membrane translocation and phosphorylation via direct interaction, attenuating the MEK/ERK/YY1 (mitogen-activated protein kinase/extracellular signal-regulated kinase kinase/yin yang 1) signal pathway, downregulating HOXA5 expression, and eventually attenuating cardiac hypertrophy. Conclusions: HINT1 protects against cardiac hypertrophy through suppressing HOXA5 expression. These findings indicate that HINT1 may be a potential target for therapeutic interventions in cardiac hypertrophy and heart failure.

ADAM23 in Cardiomyocyte Inhibits Cardiac Hypertrophy by Targeting FAK - AKT Signaling.

ADAM17 knockdown mitigates while ADAM17 overexpression aggravates cardiac fibrosis and dysfunction via regulating ACE2 shedding and myofibroblast transformation

DKK3 Overexpression Attenuates Cardiac Hypertrophy and Fibrosis in an Angiotensin-Perfused Animal Model by Regulating the ADAM17/ACE2 and GSK-3β/β-catenin Pathways

Hint1 (Histidine Triad Nucleotide-Binding Protein 1) Attenuates Cardiac Hypertrophy Via Suppressing Hoxa5 (Homeobox A5) Expression

MiR‐26a‐5p alleviates cardiac hypertrophy and dysfunction via targeting ADAM17

Loss of ADAM15 Exacerbates Transition to Decompensated Myocardial Hypertrophy and Dilation Through Activation of the Calcineurin Pathway

Cardiac Hypertrophy Is Positively Regulated by MicroRNA miR-23a

Cardiomyocyte Dimethylarginine Dimethylaminohydrolase-1 (DDAH1) Plays an Important Role in Attenuating Ventricular Hypertrophy and Dysfunction

Cardiomyocyte-specific knockout of ADAM17 ameliorates left ventricular remodeling and function in diabetic cardiomyopathy of mice

Targeted inhibition of Focal Adhesion Kinase Attenuates Cardiac Fibrosis and Preserves Heart Function in Adverse Cardiac Remodeling

Inhibition of Histone Demethylase JMJD1C Attenuates Cardiac Hypertrophy and Fibrosis Induced by Angiotensin II

Activating Transcription Factor 3 Deficiency Promotes Cardiac Hypertrophy, Dysfunction, And Fibrosis Induced By Pressure Overload

Ventricular Tachycardia, Myocardial Infarction, and Prolonged QT Interval: A Complication of Bronchoscopy

Histone lysine dimethyl-demethylase KDM3A controls pathological cardiac hypertrophy and fibrosis

Fibroblast growth factor 18 alleviates stress-induced pathological cardiac hypertrophy in male mice

LITAF acts as a novel regulator for pathological cardiac hypertrophy

Mitofusin 2 inhibits angiotensin II-induced myocardial hypertrophy.

Abstract 21116: Adenosine Kinase Regulation of Cardiomyocyte Hypertrophy

Histidine Triad Nucleotide Binding Protein 1 Attenuates Cardiac Hypertrophy via Suppressing Homeobox A5 Expression

Rare Mutations of ADAM17 from TOFs Induce Hypertrophy in Human Embryonic Stem Cell-Derived Cardiomyocytes Via HB-EGF Signaling

Hypertrophic cardiomyopathy in high-fat diet-induced obesity: role of suppression of forkhead transcription factor and atrophy gene transcription.